Search Results 1271-1280 of 15764 for alt

  1. Cancer-Associated Muscle Atrophy and Weakness: An Investigation of Etiology - Mayo Clinic

    Chronic active liver disease (Bilirubin > 17mmol/L, AST>144IU/L, or ALT>165IU/L). Contraindications to MRI (e.g., pacemaker, ferrous materials within body) ...

  2. A Study to Evaluate Ipilimumab Administered Intra-lymphatically Using the Sofusa® DoseConnect™ DEVICE with IV-administered Nivolumab in Patients with Metastatic Melanoma - Mayo Clinic

    Alanine aminotransferase (ALT) and aspartate transaminase (AST) ≤ 3.0 × ULN;; Serum creatinine ≤ 2.0 × ULN;; Calculated creatinine clearance ≥ 40 ml/min ...

  3. A Study to Evaluate AVID200 in Myelofibrosis Patients - Mayo Clinic

    ALT (SGPT) and/or AST (SGOT) ≤ 3 x upper limit of normal (ULN), or ≤ 4 x ULN (if upon judgment of the treating physician, it is believed to be due to ...

  4. Investigate the Efficacy and Safety of Carisbamate (YKP509) as Adjunctive Treatment for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults - Mayo Clinic

    Stable elevations of liver enzymes (alanine aminotransferase (ALT), and aspartate aminotransferase (AST)) due to concomitant medication(s) will be allowed if ...

  5. MK-8228 (Letermovir) PK In Pediatric Kidney Transplant Recipients - Mayo Clinic

    Has serum AST or ALT >5 x the ULN or serum total bilirubin >2.5 x ULN within 14 days before enrollment. Note: Participants who meet this exclusion criterion ...

  6. Radiation Therapy and Cisplatin With or Without Surgery in Treating Patients With Stage III-IV Oropharyngeal Cancer - Mayo Clinic

    Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) < 3 x the upper limit of normal; Serum creatinine ≤ 1.5 mg/dl and/or creatinine clearance ...

  7. Pafolacianine for Localization of Pediatric Extracranial Solid Tumors - Mayo Clinic

    ... (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), or total bilirubin. Unable or unwilling to use adequate birth control/contraceptive ...

  8. AURORA: Phase 3 Study for the Efficacy and Safety of CVC for the Treatment of Liver Fibrosis in Adults With NASH - Mayo Clinic

    ALT > 5 × ULN at Screening. HbA1c > 9% at Screening. Serum albumin < 3.5 g/dL at Screening. Estimated glomerular filtration rate (eGFR) < 50 mL/min/1.73 m^2 ...

  9. A Study to Investigate the Effectiveness and Safety of Efgartigimod Ph20 SC in Adult Participants with Active Idiopathic Inflammatory Myopathy - Mayo Clinic

    ... (ALT), based on central laboratory results; Electromyography demonstrating active disease within the past 3 months; Active dermatomyositis (DM) skin rash ...

  10. A Phase 2 Study to Evaluate the Safety, Biological Activity, and PK of ND-L02-s0201 in Subjects With IPF - Mayo Clinic

    Aspartate transaminase (AST) and alanine transaminase (ALT) < 2.5 × ULN;; Creatinine < 2 × ULN;; Serum albumin > 3.5 g/dL. Life expectancy of ≥ 12 months ...